A single-arm, multi-center phase II study of tislelizumab combined with lenvatinib and GEMOX as conversion therapy in potentially resectable locally advanced biliary tract cancer (ZSAB-TransGOLP): A primary analysis.

Authors :: Fan, Jia
Zhou, Jian
Shi, Guoming
Huang, Xiaoyong
Gao, Qiang
Li, Xiaowu
Ji, Yuan
Liang, Fei
Chen, Yi
Lu, Pinxiang
Qiu, Shuangjian
Ren, Ning
Shen, Yinghao
Xu, Yongfeng
Ding, Zhenbin
Zhu, Xiaodong
Sun, Huichuan
Shi, Yinghong
Wang, Xiaoying
Yi, Yong
Source :: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p488-488, 151p
Publication Year :: 2024

Full Text Access

Tools